Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
M. Fukuoka
Sign up to set email alerts
239
Publications
2,913
Citation Statements Received
685
Citation Statements Given
How they've been cited
5,227
131
2,762
20
How they cite others
1,398
53
628
4
Affiliations
Kindai University
,
Osaka City General Hospital
Publications
Order By: Most citations
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
Ohe
1
,
Ohashi
2
,
Kubota
3
et al.
2007
Annals of Oncology
Abstract
Show
615
31
469
3
Get article
Add to collection
Cite
A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group.
Furuse
1
,
Fukuoka
2
,
Kato
3
et al.
1993
JCO
Abstract
Show
278
4
158
1
Get article
Add to collection
Cite
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors
Nakagawa
1
,
Tamura
2
,
Negoro
3
et al.
2003
Annals of Oncology
Abstract
Show
275
4
157
0
Get article
Add to collection
Cite
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
Soria
1
,
Mauguen
2
,
Reck
3
et al.
2013
Annals of Oncology
Abstract
Show
321
8
144
1
3
Get article
Add to collection
Cite
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
Fukuoka
1
,
Niitani
2
,
Suzuki
3
et al.
1992
JCO
Abstract
Show
417
4
114
0
Get article
Add to collection
Cite
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
Tamura
1
,
Okamoto
2
,
Kashii
3
et al.
2008
Br J Cancer
Abstract
Show
195
5
106
1
Get article
Add to collection
Cite
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study
Seto
1
,
Nishio
2
,
Goto
3
et al.
2021
Lung Cancer
Abstract
Show
126
4
110
0
Get article
Add to collection
Cite
Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
Negoro
1
,
Masuda
2
,
Takada
3
et al.
2003
Br J Cancer
Abstract
Show
143
0
112
1
Get article
Add to collection
Cite
1
2
3
4
5